Compare AGX & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGX | PODD |
|---|---|---|
| Founded | 1961 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 10.3B |
| IPO Year | 1995 | 2007 |
| Metric | AGX | PODD |
|---|---|---|
| Price | $635.90 | $160.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 21 |
| Target Price | ★ $409.50 | $341.48 |
| AVG Volume (30 Days) | 307.7K | ★ 1.4M |
| Earning Date | 03-26-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.32% | N/A |
| EPS Growth | ★ 58.37 | N/A |
| EPS | ★ 3.24 | 1.30 |
| Revenue | $944,606,000.00 | ★ $2,708,100,000.00 |
| Revenue This Year | $33.81 | $24.55 |
| Revenue Next Year | $20.97 | $19.18 |
| P/E Ratio | $211.94 | ★ $121.79 |
| Revenue Growth | 8.06 | ★ 30.73 |
| 52 Week Low | $196.90 | $138.79 |
| 52 Week High | $805.75 | $354.88 |
| Indicator | AGX | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 40.87 | 55.66 |
| Support Level | $591.58 | $141.67 |
| Resistance Level | $768.89 | $161.35 |
| Average True Range (ATR) | 44.75 | 5.70 |
| MACD | -13.97 | 1.45 |
| Stochastic Oscillator | 1.86 | 77.33 |
Argan Inc is a United States-based construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC, and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Teledata, out of which Power Services derives the majority of revenue.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.